Phase 3 AMPLIFY trial showed improved efficacy in frontline CLL
The phase 3 AMPLIFY trial in frontline chronic lymphocytic leukemia showed improved efficacy with acalabrutinib plus venetoclax versus standard of care. The source text identified the study as NCT03836261.
The phase 3 AMPLIFY trial (NCT03836261) showed improved efficacy with acalabrutinib (Calquence) plus venetoclax (Venclexta) vs standard of care among patients with chronic lymphocytic leukemia (CLL). Findings from the study further show a shift away from administering standard chemoimmunotherapy to this frontline CLL population.
The trial evaluated acalabrutinib plus venetoclax vs standard of care in patients with CLL. The reported finding was improved efficacy with the acalabrutinib and venetoclax combination in the frontline setting.
No additional trial data were provided in the source text beyond the study identifier, treatment comparison, and the finding of improved efficacy.